The stock is driven by regulatory milestones, not quarterly earnings. The confirmed Q4 2026 NDA submission and pre-NDA meeting in Q3 2026 are the key catalysts. Monitor for any updates from the pre-NDA meeting and the interim SOL-R safety analysis in Q4 2026, which are required for the NDA package.
Drug in focus
OCUL drug pipeline →OTX-TKI
▲ Bullish Named in this 8-K- Impact
- Phase
- Phase 3 (pivotal completed; NDA submission imminent)
- Time to market
- If the NDA is submitted in Q4 2026 as planned, a standard FDA review would take approximately 10 months, suggesting a potential approval decision in late 2027. A priority review (possible under 505(b)(2) pathway) could shorten this to 6-8 months, potentially yielding a mid-2027 decision.
- Next catalyst
- None dated
What to watchWatch for the NDA submission announcement, expected any week given the Q4 2026 timeline confirmed on the November 9 earnings call. After submission, the next catalysts are FDA acceptance (60-day filing review) and PDUFA date assignment. A standard review would set a decision in late 2027; a priority review could accelerate to mid-2027. The stock's wide gap between current price ($6.85) and analyst targets ($25.45 mean) reflects both the binary regulatory risk and the potential for significant upside if the NDA is accepted and reviewed favorably.
How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 3 $8.40entry
- T+1 · 4mo ago +2.26%α +0.46% · $8.59
- T+5 · 3mo ago +10.00%α +7.97% · $9.24
- T+20 · 3mo ago +24.88%α +23.64% · $10.49
- T+60 · 21d ago −21.31%α −23.09% · $6.61
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Ocular Therapeutix reported Q2 2026 revenue of $13.5M (flat YoY) and a net loss of $(0.35) per share, which is a narrower loss than the $(0.39) in Q2 2025. The key catalyst is the confirmed FDA-aligned path to submit the AXPAXLI NDA for wet AMD in Q4 2026, with a pre-NDA meeting scheduled for Q3 2026. The stock will move on the regulatory clarity and the potential for a 2027 launch, not on the pre-revenue financials.
Key Financial Metrics
Key Facts
- AXPAXLI NDA submission for wet AMD on track for Q4 2026 following positive FDA Type C meeting.
- Pre-NDA meeting with FDA scheduled for Q3 2026; NDA to follow 505(b)(2) pathway, potentially accelerating review by up to 60 days.
- Total net revenue was $13.5M for Q2 2026, flat compared to Q2 2025.
- Net loss for Q2 2026 was $(78.8)M, or $(0.35) per share, vs. $(67.8)M, or $(0.39) per share in Q2 2025.
- Cash balance of $598.6M as of June 30, 2026, with expected runway into 2028.
- SOL-R trial amended to evaluate superiority vs. aflibercept (8 mg) at Week 96; topline results now expected in Q1 2028.
- HELIOS-3 trial streamlined to 620 patients evaluating once-yearly dosing (Q48W).
- Post-hoc analysis of SOL-1 shows up to 72% reduction in treatment burden vs. on-label aflibercept (2 mg).
Financial Impact
Pre-revenue biotech; $13.5M quarterly revenue from DEXTENZA is flat YoY. Cash burn of ~$78.8M per quarter. The value driver is the AXPAXLI NDA submission and potential approval, not current financials.
Risk Factors
- FDA may not accept the NDA for filing or may disagree with the 505(b)(2) pathway.
- SOL-R interim safety analysis or confirmatory evidence may be insufficient for the FDA.
- Commercial launch costs are not fully factored into the cash runway, potentially requiring future capital raises.
- SOL-R topline results delayed to Q1 2028, pushing out a potential label-expansion catalyst.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-089443 |
| Document: tm2621618d1_8k.htm | 0001104659-26-089443 |
| Document: 0001104659-26-089443-index-headers.html | 0001104659-26-089443 |
| Document: 0001104659-26-089443-index.html | 0001104659-26-089443 |
| Document: 0001104659-26-089443.txt | 0001104659-26-089443 |
| 8-K Data (Synthetic) | 0001104659-26-089443 |
Track record
20 reports on OCUL
3 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +17.73% at T+60 after the Jun 4, 2026 report. 4 of 4 went positive at some point.
Filters
- Nov 10, 20266d ago 3 Neutral 2/10 Entry $6.66 Now $6.01 −9.76% settles Nov 18
- Nov 9, 20267d ago 8-K Neutral 2/10 Entry $6.85 to $6.01 Now $6.01 −12.26% ▼ −12.26% −10.57% vs SPY
- Nov 9, 20267d ago Press Release Bearish 5/10 Entry $6.85 to $6.01 Now $6.01 +12.26% ▲ +12.26% +10.57% vs SPY
- Nov 5, 202611d ago 144 Neutral 3/10 Entry $6.60 to $6.21 Now $6.01 −8.87% ▼ −5.84% −8.43% vs SPY
- Oct 16, 20264w ago 8-K Neutral 2/10 Entry $6.29 to $6.47 Now $6.01 −4.45% ▲ +2.86% +3.01% vs SPY
- Oct 8, 20265w ago 144 Neutral 2/10 Entry $7.54 to $6.87 Now $6.01 −20.29% ▼ −8.89% −6.92% vs SPY
- Sep 2, 202610w ago Insider Cluster Neutral 4/10 Entry $10.64 to $10.49 Now $6.01 −43.52% ▼ −1.41% −0.26% vs SPY
- Aug 26, 202611w ago Insider Cluster Neutral 3/10 Entry $10.82 to $10.64 Now $6.01 −44.45% ▼ −1.66% −1.93% vs SPY
- Aug 3, 202615w ago 8-K Bullish 7/10 Viewing Entry $8.40 to $9.24 Now $6.01 −28.45% ▲ +10.00% +7.97% vs SPY
- Jun 17, 202621w ago Press Release Bullish 6/10 Entry $9.64 to $9.85 Now $6.01 −37.66% ▲ +2.18% +3.22% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers